ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Jan 2023 15:00:00 By Nasdaq GlobeNewswire

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of Age

19 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Arcutis Announces Positive Topline Results from Second Atopic Dermatitis Pivotal Phase 3 Trial of Roflumilast Cream in Adults and Children Aged 6 and Older

12 Dec 2022 07:00:53 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Dec 2022 15:01:00 By Nasdaq GlobeNewswire

Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study Evaluating ARQ-255

05 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Study Showing Significant Improvements in Itch and Itch-Related Sleep Loss with Roflumilast Cream in Adults with Plaque Psoriasis Published in American Journal of Clinical Dermatology

28 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Publishes First Environmental, Social, and Governance (ESG) Report

21 Nov 2022 08:15:00 By Nasdaq GlobeNewswire

CORRECTION -- Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older

15 Nov 2022 10:09:55 By Nasdaq GlobeNewswire

Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older

15 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Arcutis to Present at Upcoming Investor Conference

11 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

Arcutis Announces Third Quarter 2022 Financial Results and Provides Business Update

08 Nov 2022 15:02:00 By Nasdaq GlobeNewswire

Arcutis to Report Third Quarter Financial Results

25 Oct 2022 15:05:00 By Nasdaq GlobeNewswire

Nationwide Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosis

21 Oct 2022 07:00:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Oct 2022 15:00:00 By Nasdaq GlobeNewswire

Arcutis Announces Positive Topline Results from ARRECTOR Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Scalp and Body Psoriasis

26 Sep 2022 07:00:02 By Nasdaq GlobeNewswire

Journal of the American Medical Association Publishes Roflumilast Cream 0.3% Results from Pivotal DERMIS-1 and -2 Phase 3 Trials in Plaque Psoriasis

20 Sep 2022 10:07:40 By Nasdaq GlobeNewswire

New Data from Arcutis’ STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis Presented at European Academy of Dermatology and Venereology (EADV) Congress

09 Sep 2022 07:15:00 By Nasdaq GlobeNewswire

Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd.

07 Sep 2022 16:00:00 By Nasdaq GlobeNewswire

New Data from Arcutis’ Topical Roflumilast Clinical Program Presented at the European Academy of Dermatology and Venereology (EADV) Congress

06 Sep 2022 07:00:02 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Sep 2022 15:00:00 By Nasdaq GlobeNewswire